Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques
Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.
Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state…Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents
Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.
Objective: To perform a systematic review and meta-analysis on recruitment of people with Parkinson’s disease (PwP, PD) from different ethnic and racial groups in disease-modifying…Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology
Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain
Objective: The objective of this case report is to highlight the effect of a new technology, Evoked Compound Action Potential (ECAP) controlled closed-loop spinal cord…Alpha-synuclein affects PRMT5-mediated cytoprotective pathway in neuronally differentiated SH-SY5Y cell
Objective: To explore the impact of α-synuclein (αS) on PRMT5. Background: Alpha-synuclein (αS) is recognized as the pivotal molecule in the pathomechanism of Parkinson's disease.…Investigating the pathogenesis of GBA1-associated Parkinson’s disease using GBA1 isogenic iPSC lines
Objective: We aim to explore the pathogenesis of GBA1-associated synucleinopathies and discern the gain- vs. loss-of-function hypotheses by genetically engineering GBA1 in an iPSC line derived…Sphingomyelinase Activity in Patients with Sporadic Parkinson’s Disease
Objective: To measure the sphingomyelinase (ASMase) activity in sporadic PD patients and matched healthy controls and identify any clinical or biological correlation with disease’s severity.To…PARKIN gene replacement by AAV-mediated gene delivery as a therapeutic modality for PARKIN-deficient early-onset familial Parkinson’s disease
Objective: Evaluate PARKIN gene replacement by adeno-associated virus (AAV) vector as a therapeutic modality in relevant disease models of early-onset Parkinson’s Disease (EOPD). Background: Biallelic…
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 181
- Next Page »